Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies (APL)
|ClinicalTrials.gov Identifier: NCT00581763|
Recruitment Status : Completed
First Posted : December 28, 2007
Last Update Posted : June 13, 2012
|Condition or disease|
- Determine the incidence, and time frame, for aquiring aPL in a cohort of aPL-negative pediatric SLE subjects.
- Determine the incidence, and time frame, for developing a first APS-associated complication among SLE subjects with detectable aPL.
- Determine the incidence, and time frame, for developing a second APS-associated event among subjects with a history of an APS-associated event.
- Determine the incidence, and time frame, for developing SLE among subjects with a history of an APS-associated event in the absence of SLE.
- Identify laboratory and clinical predictors for the events described in aims 1-4.Research Design and Methods:
This is a prospective cohort study to determine the risk of developing aPL or APS-related symptoms in a young group of SLE and APS subjects. Patients will be followed over a ten year period and will undergo annual serologic and clinical evaluations to identify disease progression.
|Study Type :||Observational|
|Actual Enrollment :||110 participants|
|Official Title:||Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies|
|Study Start Date :||May 2001|
|Study Completion Date :||June 2011|
Those with a condition
- Evaluate changes and improve ability to determine the long-term outcome of affected individuals [ Time Frame: Ten years ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00581763
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States, 94143|
|Principal Investigator:||Emily von Scheven||University of California, San Francisco|